Different gene therapy strategies have been explored for OC management in preclinical studies, including the replacement of tumour suppressor genes to restore cell control (e.g., TP53), oncogene inhibition strategies (e.g., EGFR), suicide gene therapy with the delivery of genes encoding for toxins (e.g., HSV-TK), genetic immunopotentiation to reinforce immune response against tumour cells (e.g., IL-12A/B), antiangiogenic gene therapy (e.g., COL18A1), strategies to restore pharmacological sensitivity (e.g., survivin (BIRC5)) and cancer virotherapy (e.g., vesicular stomatitis virus). This evidence concerns the gene COL18A1 and neoplasm.